Advertisement
INCY or INSM or PFE
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Insmed Incorporated (INSM) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- INCY delivered 28% Q4 revenue growth to $1.51B, beating estimates, though shares dipped post-earnings amid mixed EPS; YTD down ~6%.
- INSM surged 67% full-year revenue to $606M on Brinsupri launch success, guiding $1B+ for 2026; YTD down ~20% from peaks, 1-year up 86%.
- PFE offers stability with 6.5% dividend yield, trading at low 9x forward P/E; YTD up ~7%, but revenue flat amid patent pressures.
- Biotech peers INCY and INSM show higher growth potential versus diversified pharma giant PFE.
- Recent volatility reflects earnings reactions and market sentiment shifts in healthcare sector.
- Valuations favor PFE on value metrics, while INSM leads momentum.
Introduction
This stock comparison examines INCY, INSM, and PFE amid evolving healthcare market dynamics, including biotech innovation and big pharma transitions. INCY and INSM represent focused biopharma plays with oncology and rare disease emphasis, contrasting PFE's broad portfolio. Traders seeking momentum from recent catalysts and investors eyeing relative performance, valuation sensitivity, and sector exposure will find value in analyzing their price behavior, sentiment shifts, and growth trajectories in recent market activity. This overview aids informed decisions on relative positioning.
INCY Overview and Recent Performance
Incyte Corporation (INCY) is a biopharmaceutical firm specializing in oncology and inflammation therapeutics, with key products like Jakafi and Opzelura driving revenue. In recent quarters, INCY reported Q4 2025 revenue of $1.51 billion, up 28% year-over-year, surpassing estimates due to higher product sales and milestones. Adjusted EPS of $1.80 missed expectations amid rising costs, contributing to a post-earnings share decline of about 4% in subsequent weeks. European approval for Zynyz in advanced anal cancer bolstered its oncology portfolio, supporting sentiment despite YTD underperformance of ~6% versus broader indices. Trading around $92, INCY reflects ~15x trailing P/E, influenced by solid revenue growth and pipeline progress amid competitive pressures.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) focuses on therapies for serious rare diseases, particularly respiratory conditions, with ARIKAYCE and newly launched Brinsupri as core offerings. Full-year 2025 revenue reached $606 million, a 67% increase, fueled by Brinsupri's $173 million and ARIKAYCE's 19% growth to $434 million. Q4 sales hit $264 million, aligning with forecasts, while guiding at least $1 billion Brinsupri revenue for 2026. Despite wider losses from R&D spend, shares reacted positively initially but pulled back ~20% YTD from highs around $140. Momentum from European approvals and pipeline advances like TPIP sustains interest, though high cash burn tempers enthusiasm in recent trading.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) is a global pharmaceutical leader with a diversified portfolio spanning vaccines, oncology, and rare diseases. Recent market activity shows stability, with shares around $26.50 up ~7% YTD, outperforming peers amid dividend appeal at 6.5% yield. Revenue trends reflect post-COVID normalization, with flat growth guidance for 2026 at $59.5-62.5 billion, supported by Prevnar and oncology expansions. Patent cliffs pose risks, but pipeline investments and cost efficiencies have stabilized sentiment. Valuation at ~9x forward P/E highlights relative value, with minor dips tied to broader sector rotations rather than company-specific events.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots selected from over 351 total bots, curated by AI analysis for superior performance in current market conditions like volatility. These bots employ diverse strategies across sectors such as semiconductors, energy, and leveraged ETFs, posting annualized returns from +19% to +210%, win rates of 53-95%, and profit factors up to 25.83. For instance, top performers include volatility bots at +210% annualized with 76% win rates and semiconductor agents exceeding +100% returns. With varying timeframes from minutes to days and robust risk metrics like profit-to-drawdown ratios over 20, they offer copy-trading options for thousands of tickers. Explore these high-conviction selections to enhance your strategy.
Head-to-Head Comparison
INCY and INSM emphasize specialized biotech models in oncology/inflammation and rare respiratory diseases, contrasting PFE’s scale across multiple therapeutic areas. Growth drivers favor INSM’s 67% revenue surge and blockbuster potential versus INCY’s 21% full-year rise and PFE’s flat outlook. Recent momentum tilts to INSM’s 86% 1-year gain, though volatile; PFE provides steadier YTD gains. Risks include pipeline setbacks for biotechs and patent losses for PFE. All share healthcare exposure, but INCY (~15x P/E) and PFE (~9x forward) appear value-oriented versus INSM’s growth premium; sentiment leans bullish on catalysts for smaller names.
Tickeron AI Verdict
Tickeron’s AI currently favors INSM due to consistent trend strength from Brinsupri’s launch trajectory and 2026 guidance implying over 100% growth, alongside robust relative positioning in rare disease momentum. While INCY offers balanced catalysts and PFE superior stability, INSM’s observable revenue inflection and pipeline probability edges it probabilistically in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s), and PFE’s FA Score reflects 2 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- INSM’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while INSM’s TA Score has 5 bullish TA indicator(s), and PFE’s TA Score reflects 3 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 4 bearish.
- INSM’s TA Score: 5 bullish, 5 bearish.
- PFE’s TA Score: 3 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а +1.07% price change this week, while INSM (@Biotechnology) price change was -1.72% , and PFE (@Pharmaceuticals: Major) price fluctuated -3.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.26%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +6.73%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
Reported Earning Dates
INCY is expected to report earnings on May 05, 2026.
INSM is expected to report earnings on Apr 30, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Biotechnology (+2.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INCY | INSM | PFE | |
| Capitalization | 19.3B | 34.5B | 155B |
| EBITDA | 1.76B | -1.18B | 16.8B |
| Gain YTD | -1.833 | -8.274 | 11.148 |
| P/E Ratio | 15.13 | N/A | 20.01 |
| Revenue | 5.14B | 606M | 62.6B |
| Total Cash | 3.58B | 1.43B | 13.6B |
| Total Debt | 40.4M | 587M | 64B |
INCY | INSM | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 14 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 79 Overvalued | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 69 | 32 | 99 | |
SMR RATING 1..100 | 32 | 100 | 73 | |
PRICE GROWTH RATING 1..100 | 48 | 41 | 28 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 35 | |
SEASONALITY SCORE 1..100 | 50 | 75 | 12 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (70) in the Biotechnology industry, and is somewhat better than the same rating for INSM (79) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than INCY’s and somewhat faster than INSM’s over the last 12 months.
INSM's Profit vs Risk Rating (32) in the Biotechnology industry is somewhat better than the same rating for INCY (69) in the Biotechnology industry, and is significantly better than the same rating for PFE (99) in the Pharmaceuticals Major industry. This means that INSM's stock grew somewhat faster than INCY’s and significantly faster than PFE’s over the last 12 months.
INCY's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for PFE (73) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that INCY's stock grew somewhat faster than PFE’s and significantly faster than INSM’s over the last 12 months.
PFE's Price Growth Rating (28) in the Pharmaceuticals Major industry is in the same range as INSM (41) in the Biotechnology industry, and is in the same range as INCY (48) in the Biotechnology industry. This means that PFE's stock grew similarly to INSM’s and similarly to INCY’s over the last 12 months.
PFE's P/E Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for INSM (100) in the Biotechnology industry, and is somewhat better than the same rating for INCY (100) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than INSM’s and somewhat faster than INCY’s over the last 12 months.
| INCY | INSM | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 66% | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 77% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 68% | 1 day ago 49% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 85% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 73% | 1 day ago 58% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 74% | 1 day ago 51% |
| Advances ODDS (%) | 1 day ago 61% | 10 days ago 71% | 10 days ago 56% |
| Declines ODDS (%) | 4 days ago 59% | 1 day ago 73% | 4 days ago 57% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 68% | 1 day ago 52% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 80% | 1 day ago 51% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NPFD | 19.18 | 0.39 | +2.08% |
| Nuveen Variable Rate Preferred & Income Fund | |||
| SEPT | 35.45 | 0.18 | +0.51% |
| AllianzIM US Equity Buffer10 Sep ETF | |||
| BSCR | 19.66 | N/A | N/A |
| Invesco BulletShares 2027 Corp Bd ETF | |||
| FTIF | 27.59 | N/A | N/A |
| First Trust Bloomberg Infl Snstv Eq ETF | |||
| PMFB | 26.73 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF - February | |||